Xarelto shows benefit for ACS patients

Xarelto (rivaroxaban) from Bayer HealthCare, cuts the rate of heart attacks, strokes, myocardial infarction, and cardiovascular death compared to placebo, according to data from a Phase III study involving patients with Acute Coronary Syndrome (ACS). However, according to this study, patients who took Xarelto also face a higher risk of major bleeding not linked to coronary artery bypass graft surgery. If Xarelto is to be FDA approved, Bayer HealthCare must ensure dosages are appropriate for maximum effectiveness and safety.